Jun 08, 2023 / 02:30PM GMT
Michael Jonathan Yee - Jefferies LLC, Research Division - Equity Analyst
Very good. Well, thank you, everyone, for joining us on our next session up here. I think our next guest needs no introduction. He's the President of Moderna, Stephen Hoge. It's good to be here with you. We just came away from ASCO. So there's some cancer topics to discuss. I'm sure the audience would love to start off with some of the respiratory disease updates.
Questions and Answers:
Michael Jonathan Yee - Jefferies LLC, Research Division - Equity AnalystAnd so maybe it would be a great place to start would be sort of your sense or Moderna sense of the state of affairs with where we are with COVID. You have guidance for COVID vaccine revenues this year. Market is a bit uncertain about that. We got RSV, and we'll talk about other stuff and also oncology.
So why don't we just start off with COVID? There's guidance. What is Moderna's sense of the state of affairs with COVID this year and your confidence around guidance and where we're going with COVID vaccines?
Trustpilot
